- Home
- MCRB vs ZNTL Comparison
MCRB vs ZNTL Comparison
Compare MCRB & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- ZNTL
- Stock Information
- Founded
- MCRB 2010
- ZNTL 2014
- Country
- MCRB United States
- ZNTL United States
- Employees
- MCRB N/A
- ZNTL N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- MCRB Health Care
- ZNTL Health Care
- Exchange
- MCRB Nasdaq
- ZNTL Nasdaq
- Market Cap
- MCRB 144.8M
- ZNTL 118.3M
- IPO Year
- MCRB 2015
- ZNTL 2020
- Fundamental
- Price
- MCRB $16.87
- ZNTL $1.34
- Analyst Decision
- MCRB Hold
- ZNTL Buy
- Analyst Count
- MCRB 3
- ZNTL 7
- Target Price
- MCRB $14.33
- ZNTL $6.17
- AVG Volume (30 Days)
- MCRB 88.5K
- ZNTL 702.2K
- Earning Date
- MCRB 11-05-2025
- ZNTL 11-10-2025
- Dividend Yield
- MCRB N/A
- ZNTL N/A
- EPS Growth
- MCRB N/A
- ZNTL N/A
- EPS
- MCRB 0.62
- ZNTL N/A
- Revenue
- MCRB $351,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- MCRB N/A
- ZNTL N/A
- Revenue Next Year
- MCRB N/A
- ZNTL N/A
- P/E Ratio
- MCRB $26.91
- ZNTL N/A
- Revenue Growth
- MCRB N/A
- ZNTL N/A
- 52 Week Low
- MCRB $6.53
- ZNTL $1.01
- 52 Week High
- MCRB $24.67
- ZNTL $4.16
- Technical
- Relative Strength Index (RSI)
- MCRB 51.80
- ZNTL 40.42
- Support Level
- MCRB $12.48
- ZNTL $1.25
- Resistance Level
- MCRB $14.35
- ZNTL $1.41
- Average True Range (ATR)
- MCRB 1.18
- ZNTL 0.10
- MACD
- MCRB 0.22
- ZNTL -0.01
- Stochastic Oscillator
- MCRB 80.50
- ZNTL 22.04
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.